Health Canada Approves Phase 1 Study of Vaporized Cannabinoid-derived Treatment PPP001 for Chronic Pain

Health Canada Approves Phase 1 Study of Vaporized Cannabinoid-derived Treatment PPP001 for Chronic Pain
Tetra BioPharma has announced that the Therapeutic Drug Directorate at Health Canada has issued a "No objection letter" in approving a Phase 1 study to test a vaporized version of PPP001 for the treatment of chronic pain, the main feature of fibromyalgia. The study will investigate the pharmacokinetics — the time the body takes to absorb, distribute, and excrete the substance — and the safety of the vaporized medicine. PPP001 is a cannabinoid-based product being tested in a Phase 3 clinical trial (NCT03339622), currently recruiting, for its efficacy in relieving pain in people with advanced cancer. This approval comes four months after the announcement of a collaboration between Tetra BioPharma and Storz & Bickel to develop a version of PPP001 administered using the Mighty Medic vaporizer — a portable herbal vaporizer approved by Health Canada for the use of cannabis. The collaboration's protocol was approved earlier this year by a Canadian
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *